Patient, Family, Caregiver Symposium 1/28 - Sign Up Today!

1-727-205-3922

1-727-205-3922

  • Home
  • About Us
    • About Us
    • Contact Us
  • What Is C. diff. ?
    • What Is C. diff.
    • C. diff. Education
    • Clinical Trials
    • Home Care
    • Nutrition
    • Probiotics
    • C diff Radio
    • Guide For School Nurses
  • Donate
  • For H/C Clinicians
    • For H/C Clinicians
    • C. diff. Education
    • C. diff. Radio
  • NEWS
  • Programs & Events
    • Support
    • Junior Infection Fighters
    • Events
    • January 28 Agenda
    • Volunteer Program
  • More
    • Home
    • About Us
      • About Us
      • Contact Us
    • What Is C. diff. ?
      • What Is C. diff.
      • C. diff. Education
      • Clinical Trials
      • Home Care
      • Nutrition
      • Probiotics
      • C diff Radio
      • Guide For School Nurses
    • Donate
    • For H/C Clinicians
      • For H/C Clinicians
      • C. diff. Education
      • C. diff. Radio
    • NEWS
    • Programs & Events
      • Support
      • Junior Infection Fighters
      • Events
      • January 28 Agenda
      • Volunteer Program
  • Home
  • About Us
  • What Is C. diff. ?
  • Donate
  • For H/C Clinicians
  • NEWS
  • Programs & Events
C Diff Foundation

Educating & advocating for C.diff. infection prevention & more worldwide

Educating & advocating for C.diff. infection prevention & more worldwideEducating & advocating for C.diff. infection prevention & more worldwide

H/C Professionals

Additional Information

 

Healthcare Professional Resources



 *PLEASE NOTE – The C Diff Foundation does not endorse any product, medication,  and/or clinical study in progress and available.    All website postings are strictly for informational purposes only. 



New guidance for C. difficile infection management in adults:

  • For patients with an initial C. difficile episode, fidaxomicin is recommended rather than a standard course of vancomycin.
  • For patients with recurrent C. difficile episodes, a standard or extended-pulsed regimen of fidaxomicin should be used rather than a standard course of vancomycin.
  • For patients with a recurrent C. difficile episode within the past 6 months, bezlotoxumab and standard-of-care antibiotics should be used rather than standard-of-care antibiotics alone.


“Head-to-head trials of differing anti-CDI recurrence strategies using narrow-spectrum antibiotics that target C. difficile, restoration of the microbiome using biotherapeutics or [fecal microbiota transplantation], or augmentation of the host immune response with agents such as bezlotoxumab given alone or in combination (eg, in combination with fidaxomicin) are needed,” the authors wrote. 2017 Guidelines in their entirety



American College of Gastroenterology (ACG)

Released updated clinical guidelines on the prevention, diagnosis, and treatment of Clostridioides difficile infections (CDI), which was recently published in The American Journal of Gastroenterology. These guidelines represent the official practice recommendations of the ACG and indicate the preferred approach to the management of adults with C.D.I..  (2021)


DIFICID®

(fidaxomicin)  tablets

This private and confidential program provides product free of charge to eligible individuals, primarily the uninsured who, without our assistance, could not afford needed Merck medicines. Individuals who don’t meet the insurance criteria may still qualify for this program if they attest that they have special circumstances of financial and medical hardship, and their income meets the program criteria. A single application may provide for up to 1 year of product free of charge to eligible individuals and an individual may reapply as many times as needed.


PATIENT ASSISTANCE PROGRAM:

Read more about the Merck

Patient Assistance Programs



See a video on how to fill out the enrollment form here


Download an enrollment form checklist


Program Contact Information


800-727-5400


915-849-1037


Hours: 8 AM – 8 PM ET
Days: Monday – Friday



ZINPLAVA (bezlotoxumab) is now available for prescription.

Ordering information is available on the brand website


What is Zinplava™ ?

ZINPLAVA™ is indicated to reduce the recurrence of Clostridioides difficile infection  in patients 18 years of age or older who are receiving antibacterial drug treatment of a

C. difficile infection  and are at a high risk for C. difficile infection recurrence.

ZINPLAVA is not indicated for the treatment of C. difficile infection.

ZINPLAVA is not an antibacterial drug.

ZINPLAVA should only be used in conjunction with antibacterial drug treatment of a  C. difficile infection.


Please see Prescribing Information for ZINPLAVA (bezlotoxumab) 


Patient Information for ZINPLAVA


Please see Prescribing Information for ZINPLAVA (bezlotoxumab) 



Full prescribing information can be read at

https://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_pi.pdf


The Merck Access Program can help answer physician’s questions about:
Insurance coverage for patients
Prior Authorizations and Appeals
Coding and Billing
Potential financial assistance options for eligible patients


Full program details can be found at:

https://www.merckaccessprogram-zinplava.com/hcp/

Also, Information about co-pay assistance for eligible, privately insured patients
Information about available independent assistance foundation support.



FIRVANQ® comes in 25 mg/mL or 50 mg/mL kits.

Each kit contains a bottle of vancomycin hydrochloride USP powder for oral solution and a bottle of grape‑flavored diluent for simple reconstitution.

References: 1. FIRVANQ® Prescribing Information. Wilmington, MA: 

 

References:

  • FIRVANQ® Prescribing Information. Wilmington, MA: Azurity Pharmaceuticals, Inc; 2020.
  • Centers for Disease Control and Prevention (CDC). 2018 annual report for the emerging infections program for Clostridium difficile infection. https://www.cdc.gov/hai/eip/pdf/cdiff/2018-CDI-Report-H.pdf. Accessed January 7, 2021.


 Firvanq is part of the Glycopeptide Antibiotics class and treats Gastrointestinal Infection and Diarrhea. Glycopeptide antibiotics are used to treat bacterial infections, lower respiratory infections, skin infections, diarrhea, and gastrointestinal infections. They work by killing the bacteria causing the infection. Firvanq is only available as a brand name drug. The lowest GoodRx price for the most common version of Firvanq is around $143.68, 16% off the average retail price of $172.06. Compare glycopeptide antibiotics. 



June 01, 2021 – in a 24-hour period without an alternative explanation and a positive stool test for C. difficile.1 … to severe or fulminant colitis.2,3 • Up to 50 percent of nursing home residents are colonized with C. difficile for the results of C. difficile test results.1 • C. difficile testing recommendations1 − Do not test  C. diff (Clostridioides difficile). Centers for Disease Control and Prevention. November 2020. … Fidaxomicin versus vancomycin for Clostridium difficile infection.

PDF Document



Agency for Healthcare Research and Quality 

Office of Communications
5600 Fishers Lane, 7th Floor
Rockville, MD 20857

Communicating by Phone with AHRQ: The public inquiries number is: (301) 427-1104.



Click HERE for SEPSIS Awareness Information



Duration of Contact Precautions for Acute-Care Settings

February 2018 – Update Published



ANTIBIOTIC INFORMATION:

Antibiotic-Resistance CDC Links Of Interest:

Core Elements:

https://www.cdc.gov/getsmart/community/improving-prescribing/core-elements/core-outpatient-stewardship.html

https://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html

https://www.cdc.gov/longtermcare/prevention/antibiotic-stewardship.html

Links to Patient Safety Atlas

Antibiotic Resistance Patient Safety Atlas: Outpatient Antibiotic Prescriptions by State Data (2011-2014)

Antibiotic Resistance Patient Safety Atlas: Hospital Antibiotic Stewardship Programs by State Data (2014-2015)   https://gis.cdc.gov/grasp/PSA/indexST.html

Antibiotic Resistance Patient Safety Atlas: Healthcare Facilities Reporting HAIs by State Data (2011-2014)


CDC Standard Precautions and OSHA Mandated PPE

Utilize healthcare professional prevention guidelines and stay safe.


For Clinicians:  6 Steps to C. diff. Prevention

  1. Prescribe and use antibiotics carefully. About 50% of all antibiotics given are not needed, unnecessarily raising the risk of C. difficile infections.
  2. Test for C. difficile when patients have diarrhea while on antibiotics or within several months of taking them.
  3. Isolate patients with C. difficile immediately.
  4. Wear gloves and gowns when treating patients with C. difficile, even during short visits. Hand sanitizer does not kill C. difficile, and handwashing may not be sufficient.
  5. Cleanroom surfaces with bleach or another EPA-approved, spore-killing disinfectant after a patient with C. difficile has been treated there.
  6. When a patient transfers, notify the new facility if the patient has a C. difficile infection.

(1) CDC Released by the CDC: February 2015



Contact C Diff Foundation  to receive your complimentary DVD

 “Raising C. diff. Awareness for Healthcare Providers” 

 since 2013 and share this important information with your staff and colleagues.


C Diff Foundation

8520 Government Drive, Ste 1, New Port Richey, FL 34654 USA

+1 727-205-3922

Copyright © 2022 Cdiff.Foundation - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Register For An Event Today!

We Look Forward To Meeting You Online & In-Person!

learnMore